ArticleHuman vaccines & immunotherapeutics2025
Gaps in vaccine clinical trials in Africa: A mixed scoping review and bibliometric analysis before, during, and post- COVID-19 pandemic.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Strengthening capacity for clinical trial monitoring in the East African community: a multi-country training programme.BMC medical education · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Africa's participation in vaccine trials has historically been limited, but the COVID-19 pandemic highlighted the need for greater involvement. This study explores vaccine clinical development in Africa, emphasizing its importance for global health security. Using a scoping review and bibliometric analysis, we examined 662 vaccine trials conducted before, during, and after the pandemic. The analysis revealed a significant increase in vaccine trials after 2018 and particularly following the end of the COVID-19 pandemic in May 2023. Most trials focused on viral infections and were single-country studies. Pharmaceutical company sponsors funded most of the earlier trials, with increased government and academic involvement post-2020. Despite progress, challenges remain in the geographic distribution of trials, the number of government-supported studies, and the diversity of conditions studied. Addressing these gaps is crucial to bolstering Africa's role in global vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.